Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Wnt-5a has tumor suppressor activity in thyroid carcinoma

Oncogene volume 24, pages 2144–2154 (2005)Cite this article

Abstract

Stabilization of β-catenin by inhibition of its phosphorylation is characteristic of an activation of the canonical Wnt/β-catenin signaling pathway and is associated with various human carcinomas. It contrasts to an as yet incompletely characterized action of an alternative noncanonical Wnt signaling pathway on neoplastic transformation. The aim of the present study was to test the effects of a member of the noncanonical Wnt signaling pathway, Wnt-5a, in primary thyroid carcinomas and in thyroid carcinoma cell lines. Compared to normal tissue Wnt-5a mRNA expression was clearly increased in thyroid carcinomas. Immunohistochemically, a bell-shaped response was observed with low to undetectable levels in normal tissue and in anaplastic tumors whereas differentiated thyroid carcinomas showed strong positive immunostaining for Wnt-5a. Transfection of Wnt-5a in a thyroid tumor cell line FTC-133 was able to reduce proliferation, migration, invasiveness and clonogenicity in these cells. These effects of Wnt-5a are associated with membranous β-catenin translocation and c-myc oncogene suppression and are mediated through an increase in intracellular Ca2+ release, which via CaMKII pathways promotes β-catenin phosphorylation. Specific inhibition of β-catenin phosphorylation by W-7, a calmodulin inhibitor, or by KN-93, a CaMKII inhibitor, supports these findings whereas PKC inhibitors were without effect. This interaction occurs downstream of GSK-3β as no Wnt-5a effect was seen on the Ser9 phosphorylation of GSK-3β. Our data are compatible with the hypothesis that Wnt-5a serves as an antagonist to the canonical Wnt-signaling pathway with tumor suppressor activity in differentiated thyroid carcinomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Ahumada A, Slusarski DC, Liu X, Moon RT, Malbon CC and Wang HY . (2002). Science, 6, 2006–2010.

  • Bui TD, Tortora G, Ciardiello F and Harris AL . (1997). Biochem. Biophys. Res. Commun., 239, 911–917.

  • Chan EF, Gat U, McNiff JM and Fuchs E . (1999). Nat. Genet., 21, 410–413.

  • Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S and Hirohashi S . (1998). Cancer Res., 58, 3526–3528.

  • Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A and Armas A . (1999). Am. J. Pathol., 155, 527–536.

  • He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW . (1998). Science, 281, 1509–1512.

  • Helmbrecht K, Kispert A, von Wasielewski R and Brabant G . (2001). Endocrinology, 142, 5261–5266.

  • Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J and Matsumoto K . (2003). Mol. Cell. Biol., 23, 131–139.

  • Jeng YM, Wu MZ, Mao TL and Chang MH . (2000). Cancer Lett., 152, 45–51.

  • Jonsson M, Dejmek J, Bendahl PO and Andersson T . (2002). Cancer Res., 15, 409–416.

  • Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW and Kirsch IR . (1997). Cancer Res., 57, 4478–4481.

  • Kobayashi K and Sagae S . (1999). Jpn. J. Cancer Res., 90, 55–59.

  • Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D and Pietsch T . (1999). Cancer Res., 59, 269–273.

  • Kuhl M, Sheldahl LC, Malbon CC and Moon RT . (2000a). J. Biol. Chem., 28, 12701–12711.

  • Kuhl M, Sheldahl LC, Park M, Miller JR and Moon RT . (2000b). Trends Genet., 16, 279–283.

  • Iozzo RV, Eichstetter I and Danielson KG . (1995). Cancer Res., 55, 3495–3499.

  • Lustig B and Behrens J . (2003). J. Cancer Res. Clin. Oncol., 129, 199–221.

  • Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ and Hanski C . (1999). Proc. Natl. Acad. Sci. USA, 96, 1603–1608.

  • Meng Q, Goldberg ID, Rosen EM and Fan S . (2000). Breast Cancer Res. Treat., 63, 147–152.

  • Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S and Redston M . (1999). Cancer Res., 59, 3346–3351.

  • Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y . (1998). Cancer Res., 58, 2524–2527.

  • Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES and Buendia MA . (1999). Am. J. Pathol., 155, 703–710.

  • Olson DJ, Gibo DM, Saggers G, Debinski W and Kumar R . (1997). Cell Growth Differ., 8, 417–423.

  • Olson DJ and Parkoff J . (1994). Cell Growth Differ., 5, 197–206.

  • Olson DJ, Oshimura M, Otte AP and Kumar R . (1998). Tumour Biol., 19, 244–252.

  • Palacios J and Gamallo C . (1998). Cancer Res., 58, 1344–1347.

  • Pandur P, Maurus D and Kuhl M . (2002). Bioessays, 10, 881–884.

  • Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ and Lee JY . (1999). Cancer Res., 59, 4257–4260.

  • Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J, Corr M and Carson DA . (2002). Oncogene, 21, 6598–6605.

  • Saneyoshi T, Kume S, Amasaki Y and Mikoshiba K . (2002). Nature, 417, 295–299.

  • Sheldahl LC, Park M, Malbon CC and Moon RT . (1999). Curr. Biol., 1, 695–698.

  • Slusarski DC, Corces VG and Moon RT . (1997a). Nature, 27, 410–413.

  • Slusarski DC, Yang-Snyder J, Busa WB and Moon RT . (1997b). Dev. Biol., 1, 114–120.

  • Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S and Nagayama M . (2003). Cancer Sci., 94, 593–597.

  • Tetsu O and McCormick F . (1999). Nature, 398, 422–426.

  • Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ and Yang Y . (2003). J. Cell Biol., 162, 899–908.

  • van der Heyden MA, Rook MB, Hermans MM, Rijksen G, Boonstra J, Defize LH and Destree OH . (1998). J. Cell Sci., 111 (Part 12), 1742–1749.

  • Veeman MT, Axelrod JD and Moon RT . (2003). Dev. Cell, 5, 367–377.

  • Woo DK, Kim HS, Lee HS, Kang YH, Yang HK and Kim WH . (2001). Int. J. Cancer, 95, 108–113.

  • Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings M and Chenevix-Trench G . (1999). Int. J. Cancer, 82, 625–629.

  • Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A and Hirohashi S . (2000). Cancer Res., 60, 4761–4766.

  • Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ and Boman BM . (2001). Cancer Res., 61, 8664–8667.

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg Str. 1, D-30625, Hannover, Germany

    N Kremenevskaja, A S Rao, C Schöfl & G Brabant

  2. Department of Pathology, Hannover Medical School, Hannover, Germany

    R von Wasielewski

  3. Experimental Pathology, Lund University, Malmö University Hospital, Malmö, Sweden

    T Andersson

Authors
  1. N Kremenevskaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R von Wasielewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A S Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Schöfl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Brabant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Brabant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kremenevskaja, N., von Wasielewski, R., Rao, A. et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24, 2144–2154 (2005). https://doi.org/10.1038/sj.onc.1208370

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208370

Keywords

This article is cited by

Search

Advanced search

Quick links